Neupré, Belgium

Michel Moutschen


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michel Moutschen: Innovator in AIDS Treatment

Introduction

Michel Moutschen is a notable inventor based in Neupré, Belgium. He has made significant contributions to the field of medicine, particularly in the treatment and prevention of AIDS. His innovative approach focuses on utilizing COX-2 inhibitors to address immunodeficiency disorders.

Latest Patents

Moutschen holds a patent for "Methods of treating and preventing AIDS using COX-2 inhibitors." This invention provides a method for treating or preventing disorders characterized by immunodeficiency, such as HIV. The patent outlines the administration of COX-2 inhibitors or their derivatives, including diisopropylfluorophosphate, L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib, or nimesulide. It also discusses the compositions and products containing these compounds for use in preparing medicaments and for treatment.

Career Highlights

Michel Moutschen has established himself as a key figure in medical research. His work has been instrumental in advancing the understanding of immunodeficiency disorders and exploring new treatment avenues. He is currently associated with Lauras AS, where he continues to innovate in the field.

Collaborations

Moutschen has collaborated with esteemed colleagues, including Kjetil Taskén and Souad Rahmouni-Piette. These partnerships have fostered a collaborative environment that enhances research and development in their shared field of expertise.

Conclusion

Michel Moutschen's contributions to the treatment of AIDS through innovative methods highlight his role as a significant inventor in the medical field. His work continues to inspire advancements in the fight against immunodeficiency disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…